The Indian Patent Office’s Draft Guidelines for Examination of Pharmaceutical Patent Applications, 2026, have drawn sharp criticism for misquoting statutory provisions and creating uncertainty in patent prosecution. Experts call for substantial revision before finalization.
Criticism Mounts Over IPO’s 2026 Draft Pharmaceutical Patent Guidelines
The Indian Patent Office (IPO) released the Draft Guidelines for Examination of Patent Applications in the Field of Pharmaceuticals, 2026, on 20 September 2026. The draft has since been met with strong opposition from legal and industry experts who argue that it misquotes key provisions of the Patents Act, 1970, particularly concerning Sections 3(d), 3(e), and novelty assessment for incremental innovations.
Among the most contentious aspects is the redefinition of 'efficacy' under Section 3(d), where the draft appears to demand clinical proof of enhanced therapeutic efficacy even for non-obvious modifications, going beyond established precedent such as Novartis v. Union of India. Critics also highlight internal inconsistencies in the treatment of salt, ester, and polymorph claims, potentially creating uncertainty in examination standards.
The 2026 Draft Guidelines risk undermining predictability in pharmaceutical patent prosecution and may deter innovation if implemented without correction.
Practitioners are urged to submit detailed comments during the consultation period. The final version could significantly impact patent strategy in the pharmaceutical sector, particularly for formulation patents and life-cycle management. Until clarity is achieved, applicants should anticipate heightened scrutiny and prepare robust data packages to support technical and therapeutic advancements.
Citations
- Patents Act, 1970, Sections 3(d), 3(e)
